Find out how we're dedicated to giving more patients hope for the future. As a diverse, growing team, everyone at exelixis plays a role in advancing our mission through our innovative drug discovery, development and commercialization efforts. Exelixis may only have one drug on the market right now, but with phase 3 results for a potential new blockbuster on the horizon and a growing pipeline, the cabometyx maker is aiming big.
Shawty Bae Biography Real Name, Age, Career, and Viral Fame
Zanzalintinib's approval in colorectal cancer and phase 3 data in renal cell carcinoma could be multi. Food and drug administration (fda) for. Exelixis shows strong momentum, fueled by cabometyx and the potential zanzalintinib launch.
Exel) today announced results from a subgroup analysis of the phase 3 cabinet pivotal trial, which showed that cabometyx® (cabozantin.
Exel) today reported financial results for the first quarter of 2026, provided an update on progress toward achieving key.
